Effects of Cannabis in Parkinson's Disease: A Systematic Review and Meta-Analysis.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2022
Historique:
pubmed: 28 12 2021
medline: 28 4 2022
entrez: 27 12 2021
Statut: ppublish

Résumé

The legalization of cannabis in many countries has allowed many Parkinson's disease (PD) patients to turn to cannabis as a treatment. As such there is a growing interest from the PD community to be properly guided by evidence regarding potential treatment benefits of cannabis. This systematic review and meta-analysis aims to compile the best available evidence to help guide patients and their family, clinicians and researchers make informed decisions. A systematic search of the literature was conducted in June 2021. Five randomized controlled studies and eighteen non-randomized studies investigated cannabis treatment in PD patients. No compelling evidence was found to recommend the use of cannabis in PD patients. However, a potential benefit was identified with respect to alleviation of PD related tremor, anxiety, pain, improvement of sleep quality and quality of life. Given the relative paucity of well-designed randomized studies, there is an identified need for further investigation, particularly in these areas.

Identifiants

pubmed: 34958046
pii: JPD212923
doi: 10.3233/JPD-212923
doi:

Substances chimiques

Analgesics 0
Medical Marijuana 0

Types de publication

Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

495-508

Auteurs

Berzenn Urbi (B)

Office for Research Governance and Development, Gold Coast Hospital and Health Service, QLD, Australia.
School of Medicine, Griffith University, QLD, Australia.

Joel Corbett (J)

Department of Neurology, Gold Coast Hospital and Health Service, QLD, Australia.

Ian Hughes (I)

Office for Research Governance and Development, Gold Coast Hospital and Health Service, QLD, Australia.

Maame Amma Owusu (MA)

Office for Research Governance and Development, Gold Coast Hospital and Health Service, QLD, Australia.

Sarah Thorning (S)

Office for Research Governance and Development, Gold Coast Hospital and Health Service, QLD, Australia.

Simon A Broadley (SA)

School of Medicine, Griffith University, QLD, Australia.
Department of Neurology, Gold Coast Hospital and Health Service, QLD, Australia.

Arman Sabet (A)

School of Medicine, Griffith University, QLD, Australia.
Department of Neurology, Gold Coast Hospital and Health Service, QLD, Australia.

Saman Heshmat (S)

School of Medicine, Griffith University, QLD, Australia.
UQCCR, Centre for Clinical Research, University of Queensland, QLD Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH